These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 27543748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J.
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [Abstract] [Full Text] [Related]

  • 3. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S.
    Ann Hepatol; 2018 Aug 24; 17(5):815-821. PubMed ID: 30145562
    [Abstract] [Full Text] [Related]

  • 4. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators.
    Liver Int; 2018 Jun 24; 38(6):1010-1021. PubMed ID: 29091342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Modi AA, Nazario HE, Gonzales GR, Gonzalez SA.
    Aliment Pharmacol Ther; 2018 May 24; 47(10):1409-1415. PubMed ID: 29569736
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N.
    Hepatology; 2015 Jul 24; 62(1):79-86. PubMed ID: 25846144
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Pyrsopoulos N, Trilianos P, Lingiah VA, Fung P, Punnoose M.
    Eur J Gastroenterol Hepatol; 2018 Jul 24; 30(7):761-765. PubMed ID: 29481384
    [Abstract] [Full Text] [Related]

  • 13. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA, Abou Mrad R, Modaresi Esfeh J, Zein NN, Eghtesad B, Zervos X, Hanouneh IA, O'Shea R, Carey WD, Alkhouri N.
    Transplantation; 2017 May 24; 101(5):996-1000. PubMed ID: 27631598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E.
    Hepatology; 2015 Jun 24; 61(6):1793-7. PubMed ID: 25846014
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
    Liao HT, Tan P, Huang JW, Yuan KF.
    Transplant Proc; 2017 Oct 24; 49(8):1855-1863. PubMed ID: 28923637
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC.
    Aliment Pharmacol Ther; 2015 Mar 24; 41(6):544-63. PubMed ID: 25619871
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.